Gene therapy: a viable therapeutic strategy for Parkinson's disease?
- PMID: 20963433
- DOI: 10.1007/s00415-010-5796-9
Gene therapy: a viable therapeutic strategy for Parkinson's disease?
Abstract
Gene therapy represents a potentially useful additional technique to ameliorate the motor symptoms of Parkinson's disease (PD), and the motor complications of its treatment. The neurodegenerative process itself, as well as the non-motor symptoms of PD, both remain less amenable to most of the current gene therapy approaches. This review presents an overview of the four gene therapies in phase I/II clinical trials, outlines some of the challenges they face, and proposes additional alternative strategies that might improve the clinical prospects of gene therapy for PD. In so doing, we hope to highlight the issue of the current absence of effective treatment for non-motor symptoms of PD and the potential of further candidate targets for gene therapy intervention that might improve upon this, for both specific individuals with genetic forms of PD as well as "sporadic" PD patients.
Similar articles
-
Human gene therapy approaches for the treatment of Parkinson's disease: An overview of current and completed clinical trials.Parkinsonism Relat Disord. 2019 Sep;66:16-24. doi: 10.1016/j.parkreldis.2019.07.018. Epub 2019 Jul 13. Parkinsonism Relat Disord. 2019. PMID: 31324556 Review.
-
Gene-based therapies in Parkinson's disease.Neurotherapeutics. 2014 Jan;11(1):60-7. doi: 10.1007/s13311-013-0233-2. Neurotherapeutics. 2014. PMID: 24129887 Free PMC article. Review.
-
From lab bench to hope: a review of gene therapies in clinical trials for Parkinson's disease and challenges.Neurol Sci. 2024 Oct;45(10):4699-4710. doi: 10.1007/s10072-024-07599-1. Epub 2024 May 25. Neurol Sci. 2024. PMID: 38795270 Review.
-
An update on gene therapy in Parkinson's disease.Curr Neurol Neurosci Rep. 2011 Aug;11(4):362-70. doi: 10.1007/s11910-011-0197-8. Curr Neurol Neurosci Rep. 2011. PMID: 21479996 Review.
-
Gene and Cell-Based Therapies for Parkinson's Disease: Where Are We?Neurotherapeutics. 2020 Oct;17(4):1539-1562. doi: 10.1007/s13311-020-00940-4. Epub 2020 Oct 30. Neurotherapeutics. 2020. PMID: 33128174 Free PMC article. Review.
Cited by
-
Parkinson's disease: an update on pathogenesis and treatment.J Neurol. 2013 May;260(5):1433-40. doi: 10.1007/s00415-013-6915-1. Epub 2013 Apr 16. J Neurol. 2013. PMID: 23589196 Review.
-
The glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue?Front Pharmacol. 2014 Jul 10;5:139. doi: 10.3389/fphar.2014.00139. eCollection 2014. Front Pharmacol. 2014. PMID: 25071571 Free PMC article. Review.
-
MiR-20a-5p Regulates MPP+-Induced Oxidative Stress and Neuroinflammation in HT22 Cells by Targeting IRF9/NF-κB Axis.Evid Based Complement Alternat Med. 2021 Jun 21;2021:6621206. doi: 10.1155/2021/6621206. eCollection 2021. Evid Based Complement Alternat Med. 2021. PMID: 34249133 Free PMC article.
-
Therapeutic efficacy of AAV8-mediated intrastriatal delivery of human cerebral dopamine neurotrophic factor in 6-OHDA-induced parkinsonian rat models with different disease progression.PLoS One. 2017 Jun 16;12(6):e0179476. doi: 10.1371/journal.pone.0179476. eCollection 2017. PLoS One. 2017. PMID: 28622392 Free PMC article.
-
Identification and Validation of Oxidative Stress-Related Hub Genes in Parkinson's Disease.Mol Neurobiol. 2025 May;62(5):5466-5483. doi: 10.1007/s12035-024-04622-6. Epub 2024 Nov 18. Mol Neurobiol. 2025. PMID: 39556279
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical